The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board Certified Neurologist with Certifications in Epilepsy, Sleep Medicine and Clinical Neurophysiology. We wish this candidate the best of success as she begins her career at Eisai reporting directly to the Chief Medical Officer of the Neurology Business Group. The Chase Group appreciates and values our continued partnership with Eisai and would like to congratulate them on securing an exceptional physician for their team. We are proud to connect life-changing executives and companies!
A Successful Placement at Eisai, Inc.
The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board Certified Neurologist with Certifications in Epilepsy, Sleep Medicine and Clinical Neurophysiology. We wish this candidate the best of success as she begins her career at Eisai reporting directly to the Chief Medical Officer of the Neurology Business Group. The Chase Group appreciates and values our continued partnership with Eisai and would like to congratulate them on securing an exceptional physician for their team. We are proud to connect life-changing executives and companies!- Categories: Life Sciences, Research & Development
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… 
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…-
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… 
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…